The elucidation of neoantigens is a critical step in predicting response to checkpoint blockade therapy and design of personalized cancer vaccines. We have developed an in silico sequence analysis method -pVACtools, to facilitate comprehensive neoantigen characterization. This modular workflow consists of tools for neoantigen prediction from somatic alterations (pVACseq and pVACfuse), prioritization and selection using a graphical web-based interface (pVACviz), and determining the optimal order of neoantigen candidates in a DNA vector-based vaccine(pVACvector).
Increasing interest in identifying the numbers and types of predicted neoantigens encoded by a cancer genome has placed an emphasis on the facility and precision of related computational prediction tools 1 . Several such efforts have been published 2, 3, 4 .
Typically, these tools start with a list of somatic variants (in VCF or other formats), with annotated protein changes, and predict the strongest MHC binding peptides (8-11-mer for class I MHC and 13-25-mer for class II) using one or more prediction algorithms 5, 6, 7 .
The predicted neoantigens are then filtered or ranked based on defined metrics including sequencing read coverage, variant allele fraction, gene expression, and differential binding compared to the wild type peptide (agretopicity index score 8 ).
However, of the small number of such prediction tools (Supp Table 1 ), most lack some key functionality, including predicting neoantigens from gene fusions, aiding optimized vaccine design for DNA cassette vaccines, and including nearby germline or somatic alterations into the candidate neoantigens 9 . An intuitive graphical user interface to visualize and efficiently select the most promising candidates is also critical to facilitate involvement of clinicians and other researchers in the process of neoantigen evaluation.
To address these limitations and to add facility for all end-users, we created a comprehensive and extensible framework for computational identification, selection, prioritization and visualization of neoantigens -'pVACtools', that facilitates each of the major components of neoantigen identification. This computational framework can be used to identify neoantigens from a variety of somatic alterations, including gene fusions and insertion/deletion frameshift mutations, both of which potentially create very strong immunogenic neoantigens 10 . Further, pVACtools can facilitate both MHC class I and II predictions, and provides an interactive display of predicted neoantigens for review by the end user.
The pVACtools workflow (Fig 1) is divided into flexible components that can be run independently. The main tools in the workflow are: (a) pVACseq: a significantly enhanced and reengineered version of our previous pipeline 11 for identifying and prioritizing neoantigens from a variety of tumor-specific alterations (b) pVACfuse: a tool for detecting neoantigens resulting from gene fusions (c) pVACviz: a graphical user interface web client for process management, visualization and selection of results from pVACseq (d) pVACvector: a tool for optimizing design of neoantigens and nucleotide spacers in a DNA vector that prevents high-affinity junctional epitopes, and (e) pVACapi: an OpenAPI HTTP REST interface to the pVACtools suite. 15 . By creating a framework that integrates many tools we allow for (a) a broader ensemble approach than IEDB, and (b) a system that other users can leverage to develop improved ensemble ranking, or to integrate proprietary or not-yet-public prediction software. Importantly, this framework enables non-informatics-savvy users to predict neoantigens from sequence variant data sets.
Once neoantigens have been predicted, the pVACseq ranking score is used to prioritize them. This score takes into account gene expression, sequence read coverage, binding affinity predictions, and agretopicity (Methods). In addition to applying strict binding affinity cutoffs, the pipeline also offers support for MHC allele-specific cutoffs 16 . Taking a step further than most commonly used approaches, we also offer cleavage position predictions via optional processing through NetChop 17 as well as stability predictions made by NetMHCstab 18 .
Previous studies have shown that the novel protein sequences produced by gene fusions frequently produce neoantigen candidates 19 . pVACfuse provides support for predicting neoantigens from such gene fusions. Fusion variants may be imported in annotated BEDPE format from any fusion caller (we used INTEGRATE-Neo 19 ). These variants are then assessed for presence of fusion neo-epitopes using predictions against any of the pVACseq-supported binding prediction algorithms.
Implementing cancer vaccines in a clinical setting requires multidisciplinary teams, many of whom may not be informatics savvy. To support this growing community of users, we developed pVACviz, which is a browser-based user interface that assists in Furthermore, to support informatics groups that want to incorporate or build upon the pVACtools features, we developed pVACapi, which provides a HTTP REST interface to the pVACtools suite. Currently, it provides the API that pVACviz uses to interact with the pVACtools suite. Advanced users could develop their own user interfaces, or use the API to control multiple pVACtools installations remotely over an HTTP network.
Once a list of neoantigen candidates has been prioritized and selected, the pVACvector utility can be used to aid in the construction of DNA-based cancer vaccines. The input is either the output file from pVACseq or a fasta file containing peptide sequences, and pVACvector returns a neoantigen sequence ordering that minimizes the effects of junctional epitopes (which may create novel antigens) between the sequences. This is accomplished by using the core pVACseq services to predict the binding scores for each junctional peptide and by testing junctions with spacer 20 amino acid sequences that may help to reduce reactivity. The final vaccine ordering is achieved through a simulated annealing procedure that returns a near-optimal solution, when one exists.
pVACtools has been used to predict and prioritize neoepitopes for several neoantigen studies [21] [22] [23] and cancer vaccine clinical trials (e.g. NCT02348320 and NCT03122106).
We also have a large external user community (the original 'pvacseq' package has been downloaded over 37,000 times from PyPi, and the 'pvactools' package has been downloaded over 9,000 times) that has been actively evaluating and using these packages for their neoantigen analysis, and has also helped in the subsequent refinement of pVACtools through feedback.
To demonstrate the utility and performance of the pVACtools package, we downloaded exome sequencing and RNA-Seq data from The Cancer Genome Atlas (TCGA) 24 from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma, and used patient-specific MHC Class I alleles ( Supp Fig 1) to determine neoantigen candidates for each cancer. By extending support for additional variant types as well as prediction algorithms, we produced 42% more neoantigens versus the previous version of pVACseq 11 .
(Supplementary Data)
As reported from our demonstration analysis, a typical tumor has too many possible neoantigen candidates to be practical for a vaccine. There is therefore a critical need for a tool that takes in the input from a standard sequencing analysis pipeline and reports a filtered and prioritized list of neoantigens. pVACtools enables a streamlined, accurate and user-friendly analysis of neoantigenic peptides from NGS cancer datasets. This suite offers a complete and easily configurable end-to-end analysis, starting from somatic variants and gene fusions (pVACseq and pVACfuse respectively), through filtering, prioritization, and visualization of candidates (pVACviz), and determining the best arrangement of candidates for a DNA vector vaccine (pVACvector). Furthermore, by supporting additional classes of variants as well as gene fusions, we offer an increase in the number of predicted epitopes which is even more important in the case of low mutational burden tumors. Finally, by extending support for multiple binding prediction algorithms, we allow for a consensus approach. The need for this integrated approach is made abundantly clear by the high disagreement between these algorithms observed in our demonstration analyses (Supplementary Data).
The results from pVACtools analyses are already being used in cancer immunology studies, including studying the relationship between tumor mutation burden and neoantigen load to predict response in checkpoint blockade therapy trials and the design of cancer vaccines in ongoing clinical trials. We anticipate that pVACtools will make such analyses more robust, reproducible, and facile as these efforts continue. 28 HaplotypeCaller to perform germline variant calling using default parameters. These calls were refined using VariantRecalibrator in accordance with GATK Best Practices 29 . Somatic and germline missense variant calls from each sample were then combined using GATK's CombineVariants, and the variants were subsequently phased using GATK's ReadBackedPhasing algorithm.
Additional information
Phased Somatic VCF files were annotated with RNA depth and expression information using VCF annotation tools (vatools.org). We restricted our analysis to only consider 'PASS' variants in these VCFs as these are higher confidence than the raw set, and the variants were annotated using the "--pick" option in VEP.
Existing in silico HLA typing information was obtained from The Cancer Immunome Atlas (TCIA) database 30 .
Neoantigen prediction
The VEP-annotated VCF files were then run through pVACseq using all eight Class I prediction algorithms and for epitope lengths 8-11. For the demonstration analysis, we limited our prediction to only MHC Class I alleles due to availability of HLA typing information from TCIA, though predictions of Class II can be just as easily generated using pVACtools.
Ranking of Neoantigens
To help prioritize neoantigens, a ranking score is assigned where each of the following four criteria are assigned a rank-ordered value (where the worst = 1): . This score is not meant to be the final word on peptide suitability for vaccines, but was designed to be a useful metric.
Pipeline for creation of pVACtools input files pVACtools is designed to support a standard VCF variant file format and thus, should be compatible with many existing variant calling pipelines. However, as a reference, we provide the following description of our current somatic and expression analysis pipeline (manuscript in preparation) which has been implemented using docker, CWL 36 , and Variant coverage is assessed using bam-readcount (https://github.com/genome/bam-readcount) for both the tumor and normal DNA exome data and is also annotated into the VCF output using VCF-annotation-tools(vatools.org).
Our pipeline also generates a phased-VCF file by combining both the somatic and germline variants and running the sorted combined variants through GATK ReadBackedPhasing.
For RNA-seq data, the pipeline first trims the adapter sequence using flexbar 44 and aligns the patient's tumor RNA-seq data using HISAT2 45 . Two different methods, Stringtie 46 and Kallisto 47 , are employed for evaluating both the transcript and gene expression values. Additionally, coverage support for variants in RNA-seq data can also be assessed through bam-readcount. This information is added to the VCF using VCFannotation-tools and serves as an input for neoantigen prioritization using pVACtools.
Optionally, our pipeline can also run HLA-typing in silico using OptiType 48 when clinical HLA typing is not available.
Implementation pVACtools is written in Python3. The individual tools are implemented as separate command line entry points that can be run using the `pvacseq`, `pvacfuse`, `pvacvector`, `pvacapi`, and `pvacviz` commands to run the respective tool. pVACapi is required to run pVACviz so both the `pvacapi` and `pvacviz` command need to be executed in separate terminals. For pVACseq, the PyVCF package is used for parsing the input VCF files. The mhcflurry and mhcnuggets packages are used to run the MHCflurry and MHCnuggets prediction algorithms, respectively. The pandas package is used for data management while filtering and ranking the neoantigen candidates in pVACseq and pVACfuse. The simanneal package is used for the simulated annealing procedure when running pVACvector. pVACapi is implemented using Flask and Bokeh. The pVACviz client is written in TypeScript using the Angular web application framework, the Clarity UI component library, and the ngrx library for managing application state. The test suite is implemented using the Python unittest framework and GitHub integration tests are run using travis-ci (travis-ci.org). Code changes are integrated using GitHub pull requests (https://github.com/griffithlab/pVACtools/pulls). Feature additions, user requests, and bug reports are managed using the GitHub issue tracking (https://github.com/griffithlab/pVACtools/issues). User documentation is written using the reStructuredText markup language and the Sphinx documentation framework (sphinx-doc.org). Documentation is hosted on Read The Docs (readthedocs.org).
Data availability
Data from 100 cases each of melanoma, hepatocellular carcinoma and lung squamous cell carcinoma were obtained from TCGA and downloaded via the Genomics Data Commons (GDC). This data can be accessed under dbGaP study accession phs000178. Data for demonstration and analysis of fusion neoantigens was downloaded from the Github repo for Integrate (https://github.com/ChrisMaherLab/INTEGRATE-Vis/tree/master/example).
Software availability:
The pVACtools codebase is hosted publicly on GitHub at https://github.com/griffithlab/pVACtools and https://github.com/griffithlab/BGA-interfaceprojects (pVACviz 
